Verastem Slashes Staff After Mesothelioma Failure
This article was originally published in Scrip
Verastem Inc. is slashing its head count by 50%, or 20 employees, as the company continues to regroup after lead drug candidate VS-6063 failed to show an efficacy benefit for mesothelioma patients at an interim analysis in a Phase II clinical trial.
You may also be interested in...
Duvelisib, licensed from Infinity in 2016, reduces risk of disease progression or death compared to Arzerra in a Phase III study in refractory CLL/SLL. Verastem hopes to file an NDA during the first half of 2018.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
‘Wartime’ contract with BARDA will fund up to $268.8m in production site upgrades so Merck can also produce other COVID-19 vaccines and therapeutics as needed.